Evidence map›Paper›PMID 42730229›Full record

ArticleInternational journal of pharmaceutics: X2026

The carbon footprint of Chimeric Antigen Receptor-T cell manufacturing processes.

Wietske E van der Bijl, Bahez Gareb, Koen M Klomberg, Edwin Bremer, Tom van Meerten, Thijs H Oude Munnink, Bart G J Dekkers

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of pharmaceutics: X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Wietske E van der BijlDepartment of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Bahez GarebDepartment of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Koen M KlombergDepartment of Hematology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Edwin BremerDepartment of Hematology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Tom van MeertenDepartment of Hematology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Thijs H Oude MunninkDepartment of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Bart G J DekkersDepartment of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chimeric Antigen Receptor T (CAR-T) cell therapy is an established treatment for haematological malignancies, yet the environmental impact of its manufacturing and administration remains unexplored. As healthcare systems aim to reduce their carbon footprint, understanding the climate impact of CAR-T cell manufacturing is essential. The objective of this study was to quantify the carbon footprint, expressed in CO

Indexed as

Carbon footprintChimeric Antigen Receptor T (CAR-T) cell therapyLife cycle assessment

Identifiers

PMID42730229
PMCPMC13564128

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.